{Reference Type}: Journal Article
{Title}: Injectable long-acting formulations (ILAFs) and manufacturing techniques.
{Author}: Thapa Magar K;Boucetta H;Zhao Z;Xu Y;Liu Z;He W;
{Journal}: Expert Opin Drug Deliv
{Volume}: 21
{Issue}: 6
{Year}: 2024 Jun 17
{Factor}: 8.129
{DOI}: 10.1080/17425247.2024.2374807
{Abstract}: UNASSIGNED: Most therapeutics delivered using short-acting formulations need repeated administration, which can harm patient compliance and raise failure risks related to inconsistent treatment. Injectable long-acting formulations (ILAFs) are controlled/sustained-release formulations fabricated to deliver active pharmaceutical ingredients (APIs) and extend their half-life over days to months. Longer half-lives of ILAFs minimize the necessity for frequent doses, increase patient compliance, and reduce the risk of side effects from intravenous (IV) infusions. Using ILAF technologies, the immediate drug release can also be controlled, thereby minimizing potential adverse effects due to high initial drug blood concentrations.
UNASSIGNED: In this review, we have discussed various ILAFs, their physiochemical properties, fabrication technologies, advantages, and practical issues, as well as address some major challenges in their application. Especially, the approved ILAFs are highlighted.
UNASSIGNED: ILAFs are sustained-release formulations with extended activity, which can improve patient compliance. ILAFs are designed to deliver APIs like proteins and peptides and extend their half-life over days to months. The specific properties of each ILAF preparation, such as extended-release and improved drug targeting capabilities, make them an effective approach for precise and focused therapy. Furthermore, this is especially helpful for biopharmaceuticals with short biological half-lives and low stability since most environmental conditions can protect them from sustained-release delivery methods.